Private Label vs White Label Peptides: Who Owns Recalls

Private label and white label peptide agreements decide who becomes FDA's labeler of record and who inherits recall-initiation duty, and that allocation is set by supply-agreement language, not by whose name is on the vial.

Two contract structures, one regulatory question: who is the labeler of record

Private label and white label agreements assign FDA registration and listing duties differently, and that assignment — not the marketing label — decides who FDA contacts first when a lot fails. In a white label arrangement, the contract manufacturer keeps its own FDA labeler code and registration on the finished product; the buyer's brand name sits on the vial without transferring any registration obligation. In a private label arrangement, a distributor commissions the formulation and controls the packaging artwork, but may or may not register itself with FDA as the entity legally responsible for that product's listing. Both structures put a buyer's name on a vial. Only one of them makes that buyer accountable to FDA when something goes wrong.⁴

FDA does not use the marketing vocabulary of private label or white label at all. Its regulation, 21 CFR 207.1, defines a category called the private label distributor, and that category — not a supply contract's cover page — is what determines who FDA calls when a lot fails testing.⁴

A distributor that never registers or lists is not exempt from FDA's attention — it is simply invisible in FDA's own listing system until an inspection, a competitor complaint, or a lot failure forces the question. At that point, the supply agreement a buyer signed months earlier is the only document that says who was supposed to be visible.⁴

What 21 CFR 207.1 actually assigns to a private label distributor

21 CFR 207.1 defines a private label distributor as a person who did not manufacture, repack, relabel, or salvage a drug but under whose label or trade name the drug is commercially distributed. The regulation does not care who designed the artwork or negotiated price. It cares about who performed the physical acts of manufacturing versus who merely put a name on the finished product. A company can control formulation specifications, packaging design, and every purchase order, and still be, in FDA's language, a distributor rather than a manufacturer.⁴

• Did not manufacture, repack, relabel, or salvage the drug itself
• Distributes the drug under its own label or trade name
• May register with FDA and elect its own labeler code, or decline to do so
• Remains distinct in FDA's system from the contract manufacturer that physically produced the lot⁴

That distinction is not academic. FDA lets a private label distributor choose whether to carry its own listing obligation, and the choice a buyer never makes is still a choice FDA records.⁴

This is why the marketing terms private label and white label collapse into a single regulatory category the moment FDA opens a file. Both describe a distributor's brand sitting on someone else's manufacturing. Neither term tells FDA, or a buyer's own legal counsel, who carries the listing obligation — only the election described in the next section does that.⁴

The listing election: your own labeler code, or default to the manufacturer

A private label distributor faces one real choice under this framework: register with FDA and list the product under its own labeler code, or decline and let the listing sit under the contract manufacturer's registration. FDA's labeler guidance describes a labeler as any firm that manufactures or distributes a drug — including a repackager or relabeler — and it is the entity to which the agency assigns a labeler code and, by extension, a National Drug Code segment. Electing that code puts the distributor's own establishment identifier into the NDC Directory as the entity of record.^1,4

FDA's April 2019 warning letter to Ecometics, Inc. shows what happens when a private label distributor stays silent on that election. The letter confirms that even a contract manufacturer is required to register its facility and list all drugs manufactured there — and it goes further, stating that if the private label distributor does not elect to list the drug under its own code, the listing obligation defaults to the contract manufacturer. That default is not a courtesy. It means FDA's file, and any recall correspondence FDA initiates, names whichever party actually filed the listing — which, absent an affirmative election, is the factory, not the brand.⁴

Even though you are a contract manufacturer, you are still required to register your facility and list all drugs manufactured in your facility.

FDA Warning Letter to Ecometics, Inc., April 16, 2019⁴

That default matters most at the moment nobody wants to think about: when a lot fails and someone has to be named in a recall notice. A supply agreement that never mentions listing election has already answered that question, just not necessarily in the buyer's favor.⁴

Form FDA 2658 and why FDA tracks this election as a distinct category

FDA does not treat the private-label decision as informal industry practice. Form FDA 2658, Registered Establishments' Report of Private Label Distributors, exists so that a registered manufacturing establishment can report each private label distributor associated with its listed drugs. The form's existence is itself evidence: FDA maintains private-label distributor status as a distinct registration category inside its drug establishment and listing system, separate from the manufacturer's own record and separate from a standard labeler registration.⁵

For a buyer, that has a practical consequence beyond paperwork. If a contract manufacturer files Form FDA 2658 naming a buyer as its private label distributor, that filing exists in FDA's system whether or not the buyer's own supply agreement addresses it. A buyer who never asked whether it would be named on that form should assume the answer is already on file with FDA, not still open for negotiation — the question to put to the contract manufacturer directly, before signing, is whether that filing already exists.⁵

The practical reason to care is timing, not curiosity. A buyer that discovers its private-label status only after a lot recall begins is negotiating documentation under deadline pressure that Form FDA 2658 already resolved months earlier, one way or the other, without the buyer's input.⁵

Pooled lot versus dedicated lot: what a white label buyer actually shares

The labeler question determines who FDA calls. The lot question determines what a buyer is actually exposed to before FDA calls anyone. The table below sets out what separates a dedicated lot from a pooled lot in practice, and what each arrangement costs a buyer when a lot fails.^4,9

FDA's December 2024 warning letter to Summit Research Peptides documents enforcement action against a peptide seller for manufacturing and quality-control violations traced to the facility and lot record, not to the brand name on the label. The pattern illustrated there — regulators tracing a violation to the physical batch regardless of whose name sits on the shipment — is exactly the exposure a buyer inherits by drawing from a pooled lot: a single adverse finding on the parent batch reaches every split shipment carrying its lot code, regardless of whose label sits on the box.⁹

A buyer cannot verify lot structure by inspecting a certificate of analysis alone; a CoA traces to a lot number, and a shared lot number is exactly what makes a pooled arrangement invisible until a downstream complaint forces a look at the parent batch. The only way to know in advance is to ask the contract manufacturer directly whether a given purchase order draws from a dedicated lot or a pooled one, and to get that answer in writing before the certificate of analysis is the first place it shows up.^4,9

Recall initiation is not the manufacturer's job alone

FDA's regulations at 21 CFR Part 7 define the recalling firm as the firm that initiates a recall, or, in an FDA-requested recall, the firm with primary responsibility for the manufacture and marketing of the product. That definition does not say the manufacturer. It says the firm responsible for marketing — language broad enough to reach a private label distributor whose name is the one customers and downstream accounts actually recognize.⁶

A recalling firm should identify, in its recall strategy, the level of the product distribution chain to which the recall is to extend, and a notified consignee is expected to carry out its own recall procedures to extend the recall to its own direct accounts.

21 CFR Part 7, FDA Recall Guidance⁶

In practice, this means a private label distributor holding its own accounts — resellers, clinics, downstream purchasers — is expected to run its own extension of any recall a contract manufacturer initiates upstream. A supply agreement that assumes the manufacturer handles the recall describes a step FDA's own guidance places on the distributor too, not a step the manufacturer can absorb alone.⁶

None of this requires FDA to name the private label distributor first. A recall can originate entirely at the manufacturer level and still reach a point, several accounts downstream, where the private label distributor's own records — not the manufacturer's — are the only ones that show where the affected lot actually went.⁶

Trading partner obligations under the Drug Supply Chain Security Act apply regardless of label

DSCSA traceability duties attach to the position a firm occupies in the distribution chain, not to whether its name appears on the label. FDA's guidance on identifying trading partners under the Act makes clear that manufacturers, repackagers, wholesale distributors, and dispensers each carry defined obligations, and a private label distributor that takes possession of product and moves it into commerce occupies one of those defined roles whether its supply agreement says so or not.⁶

That is the second place where silence in a contract does not create an exemption. A buyer who negotiates a private label deal without addressing which party holds transaction history, transaction statements, and transaction information for DSCSA purposes has not avoided the obligation — it has left FDA's default allocation, and the contract manufacturer's own recordkeeping practice, to decide who actually holds the paper when a state board or FDA investigator asks for it.⁶

Neither private label nor white label status appears anywhere in the statute's definitions. DSCSA obligations attach to trading partner roles — manufacturer, repackager, wholesale distributor, dispenser — and a distributor that never manufactured a single vial can still occupy one of those roles the moment it takes title to product and moves it toward a downstream buyer.⁶

Four terms to put in the supply agreement before the first purchase order

Every allocation described above is set by contract language that most supply agreements never mention. A buyer negotiating a private label or white label arrangement should require four specific terms before signing, not after a lot fails.^4,5,6

1. A stated labeler-code election: either the buyer registers and lists under its own code, or the agreement names the contract manufacturer as listing party and states that fact in writing — not by omission.
2. A Form FDA 2658 clause: written confirmation of whether the manufacturer has filed, or will file, Form FDA 2658 naming the buyer as private label distributor, and a notice obligation if that filing changes.
3. A dedicated-lot default, with pooled-lot exceptions named explicitly: the agreement should state whether purchase orders draw from dedicated lots, and if pooled lots are used, disclose that fact per shipment rather than leaving it to the certificate of analysis to reveal after delivery.
4. A recall-extension clause assigning DSCSA recordkeeping and Part 7 extension duty by name: which party holds transaction history, and which party is contractually obligated to notify its own direct accounts if the manufacturer initiates a recall upstream.^4,5,6

Each term maps directly to one of the regulatory gaps described above: the labeler-code term closes the 21 CFR 207.1 election gap, the Form FDA 2658 term closes the registration-visibility gap, the lot-disclosure term closes the pooled-exposure gap, and the recall-extension term closes the Part 7 and DSCSA gap. A supply agreement missing any one of the four has left that gap open, whether or not either party noticed.^5,6

They require asking before the purchase order is placed, because every one of them is currently being decided by default — FDA's default, not the buyer's — in agreements that stay silent.⁴